Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.
Details